| 16.67 0.68 (4.25%) | 03-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 21.02 |
1-year : | 24.55 |
| Resists | First : | 18 |
Second : | 21.02 |
| Pivot price | 16.27 |
|||
| Supports | First : | 16.15 |
Second : | 15.02 |
| MAs | MA(5) : | 16.02 |
MA(20) : | 16.14 |
| MA(100) : | 16.55 |
MA(250) : | 13.29 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 41.8 |
D(3) : | 32.9 |
| RSI | RSI(14): 50.9 |
|||
| 52-week | High : | 21.34 | Low : | 7.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PHAR ] has closed below upper band by 28.4%. Bollinger Bands are 48.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 9 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 17.34 - 17.4 | 17.4 - 17.48 |
| Low: | 15.86 - 15.92 | 15.92 - 16 |
| Close: | 16.54 - 16.65 | 16.65 - 16.78 |
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.
Tue, 03 Mar 2026
Pharming Group Gears Up to Report Q4 Earnings: What's in the Cards? - Nasdaq
Tue, 03 Mar 2026
Pharming Group Prepares to Announce Q4 Results: What Can Investors Expect? - Bitget
Thu, 26 Feb 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR - PR Newswire
Thu, 26 Feb 2026
Pharming Group sets March 12 call on 2025 results and update - Stock Titan
Thu, 26 Feb 2026
Pharming Group to report fourth quarter and full year 2025 financial results and provide business update on March 12 - GlobeNewswire
Tue, 17 Feb 2026
Pharming Group to present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 70 (M) |
| Shares Float | 488 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 9 (K) |
| Shares Short P.Month | 17 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.52 |
| Profit Margin | 0.1 % |
| Operating Margin | 26.6 % |
| Return on Assets (ttm) | 5.7 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 30 % |
| Gross Profit (p.s.) | 4.67 |
| Sales Per Share | 5.19 |
| EBITDA (p.s.) | 0.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 53 (M) |
| Levered Free Cash Flow | 44 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 31.45 |
| Price to Sales | 3.2 |
| Price to Cash Flow | 21.77 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|